AIM: Pharmacologic agents that affect autophagy were tested for their abilities to enhance macrophage nanoformulated antiretroviral drug (ARV) depots and its slow release. METHODS: These agents included URMC-099, rapamycin, metformin, desmethylclomipramine, 2-hydroxy-β-cyclodextrin (HBC) and clonidine. Each was administered with nanoformulated atazanavir (ATV) nanoparticles to human monocyte-derived macrophages. ARV retention, antiretroviral activity and nanocrystal autophagosomal formation were evaluated. RESULTS: URMC-099, HBC and clonidine retained ATV. HBC, URMC-099 and rapamycin improved intracellular ATV retention. URMC-099 proved superior among the group in affecting antiretroviral activities. CONCLUSION: Autophagy inducing agents, notably URMC-099, facilitate nanoformulated ARV depots and lead to sustained release and improved antiretroviral responses. As such, they may be considered for development as part of long acting antiretroviral treatment regimens.
AIM: Pharmacologic agents that affect autophagy were tested for their abilities to enhance macrophage nanoformulated antiretroviral drug (ARV) depots and its slow release. METHODS: These agents included URMC-099, rapamycin, metformin, desmethylclomipramine, 2-hydroxy-β-cyclodextrin (HBC) and clonidine. Each was administered with nanoformulated atazanavir (ATV) nanoparticles to human monocyte-derived macrophages. ARV retention, antiretroviral activity and nanocrystal autophagosomal formation were evaluated. RESULTS:URMC-099, HBC and clonidine retained ATV. HBC, URMC-099 and rapamycin improved intracellular ATV retention. URMC-099 proved superior among the group in affecting antiretroviral activities. CONCLUSION: Autophagy inducing agents, notably URMC-099, facilitate nanoformulated ARV depots and lead to sustained release and improved antiretroviral responses. As such, they may be considered for development as part of long acting antiretroviral treatment regimens.
Authors: Huanyu Dou; Christopher J Destache; Justin R Morehead; R Lee Mosley; Michael D Boska; Jeffrey Kingsley; Santhi Gorantla; Larisa Poluektova; Jay A Nelson; Mahesh Chaubal; Jane Werling; James Kipp; Barrett E Rabinow; Howard E Gendelman Journal: Blood Date: 2006-06-29 Impact factor: 22.113
Authors: Upal Roy; JoEllyn McMillan; Yazen Alnouti; Nagsen Gautum; Nathan Smith; Shantanu Balkundi; Prasanta Dash; Santhi Gorantla; Andrea Martinez-Skinner; Jane Meza; Georgette Kanmogne; Susan Swindells; Samuel M Cohen; R Lee Mosley; Larisa Poluektova; Howard E Gendelman Journal: J Infect Dis Date: 2012-07-17 Impact factor: 5.226
Authors: D C Kalter; M Nakamura; J A Turpin; L M Baca; D L Hoover; C Dieffenbach; P Ralph; H E Gendelman; M S Meltzer Journal: J Immunol Date: 1991-01-01 Impact factor: 5.422
Authors: Cristin D Davidson; Nafeeza F Ali; Matthew C Micsenyi; Gloria Stephney; Sophie Renault; Kostantin Dobrenis; Daniel S Ory; Marie T Vanier; Steven U Walkley Journal: PLoS One Date: 2009-09-11 Impact factor: 3.240
Authors: Priyanka Saminathan; Bhavesh D Kevadiya; Daniel F Marker; Howard E Gendelman; Santhi Gorantla; Harris A Gelbard Journal: J Neuroimmune Pharmacol Date: 2019-01-07 Impact factor: 4.147